Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.

Abstract

Therapy for endocarditis due to Pseudomonas aeruginosa is complicated by the emergence of resistance during therapy, lack of universally available synergistic antimicrobial agents, and unacceptably high morbidity and mortality rates. The authors report a case of aortic valve endocarditis due to P. aeruginosa in which resistance to piperacillin developed during combined therapy with tobramycin. Bacteriologic cure was obtained with a combination of imipenem/cilastatin and tobramycin. The authors review six other cases of P. aeruginosa endovascular infections treated with imipenem.

• Authors: C J Fichtenbaum, M J Smith
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 14 Issue 1 Pg. 353-4 (Jan 1992) ISSN: 1058-4838 [Print] United States
• PMID: 1571451 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Drug Combinations
• Cilastatin
• Imipenem
• Cilastatin, Imipenem Drug Combination
• Tobramycin

Topics

• Adult
• Anti-Bacterial Agents (therapeutic use)
• Cilastatin (therapeutic use)
• Cilastatin, Imipenem Drug Combination
• Drug Combinations
• Drug Therapy, Combination (therapeutic use)
• Endocarditis, Bacterial (drug therapy)
• Humans
• Imipenem (therapeutic use)
• Male
• Pseudomonas Infections (drug therapy)
• Tobramycin (therapeutic use)